Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06716580 · ClinicalTrials.gov registry record · NA
EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
A NA study of Lung Cancer and EGFR Gene Mutation, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 6
- Study locations
NCT06716580: Recruiting NA study of Lung Cancer and EGFR Gene Mutation, sponsored by Dana-Farber Cancer Institute.
NCT06716580 is a NA study of Lung Cancer and EGFR Gene Mutation that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 1,000 participants, roughly in line with the 933-participant average among 409 other Lung Cancer trials with a reported enrollment target. The trial reports 6 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06716580, a NA study of Lung Cancer and EGFR Gene Mutation, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 6
- Study locations
Study Summary
This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DNA (cfDNA) Assay
Primary Outcome
The proportion of participants with a positive assay result who are subsequently diagnosed with lung cancer through clinical pathology, among all participants tested with the assay.
Conditions Studied
Interventions
- DEVICE Circulating Tumor DNA (ctDNA) Assay
Study Locations (6)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute at Steward St. Elizabeth's - Brighton
- Dana-Farber Cancer Instiute Merrimack Valley - Methuen
- Dana-Farber Cancer Institute South Shore - South Weymouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2030-09-01 |
| Phase | NA |
What NCT06716580 shows while recruiting
NCT06716580 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 933-participant average among 409 other Lung Cancer trials with a reported enrollment target.
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Circulating Tumor DNA (ctDNA) Assay is the first listed.
NCT06716580 lists 6 locations in 1 state (Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06716580 about?
NCT06716580 is a clinical study titled "EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations". This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DN...
What is the current status of trial NCT06716580?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2025-04-01. Estimated completion is 2030-09-01.
What conditions does trial NCT06716580 study?
This clinical trial studies the following conditions: Lung Cancer, EGFR Gene Mutation.
What interventions are being tested in trial NCT06716580?
The interventions under investigation include: Circulating Tumor DNA (ctDNA) Assay (DEVICE).
Who is sponsoring clinical trial NCT06716580?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06716580 being conducted?
This trial has 6 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06716580's enrollment target sits among peer trials
1,000 48th of 409 higher than 360 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
RECRUITING · NA
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI